Habiba Atta

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, not treatment failure.

Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said Richard Nowak, MD, MS

The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

New Harris Poll data show mental health, access, and postpartum care gaps persist for US mothers, with Black and Hispanic women hit hardest.

The ACCESS program gave underinsured patients free specialty eye care at one center, restoring vision and cutting disability costs, a study found.

Follow-up length varied by subgroup in the MINT trial, but inebilizumab cut exacerbations and rescue therapy use consistently.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, said.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

Traveling a greater distance for cataract surgery significantly lowered the odds of receiving it, with each 100 miles cutting odds by 14% overall.

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.

In this analysis, all 4 biologic classes showed reduced risk, and the CV benefit remained consistent across White, Black, and Asian patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.

AI-based diabetic retinopathy screening in primary care meaningfully lowers overall health care costs compared with physician-referral screening.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.